{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.7643.2.1006","meta":{"versionId":"6","lastUpdated":"2019-01-08T01:00:08.000-05:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.7643.2.1006","version":"20190108","name":"Checkpoint Inhibitors with Potential to Cause Grade 3 or Higher Fatigue","status":"active","date":"2019-01-08T01:00:08-05:00","publisher":"Oncology Nursing Society Steward","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","concept":[{"code":"1657005","display":"40 ML ipilimumab 5 MG/ML Injection"},{"code":"1657012","display":"10 ML ipilimumab 5 MG/ML Injection"},{"code":"1657190","display":"4 ML nivolumab 10 MG/ML Injection"},{"code":"1657195","display":"10 ML nivolumab 10 MG/ML Injection"},{"code":"1657746","display":"pembrolizumab 50 MG Injection"},{"code":"1657750","display":"4 ML pembrolizumab 25 MG/ML Injection"},{"code":"1792780","display":"20 ML atezolizumab 60 MG/ML Injection"},{"code":"1875542","display":"10 ML avelumab 20 MG/ML Injection"},{"code":"1919507","display":"2.4 ML durvalumab 50 MG/ML Injection"},{"code":"1919515","display":"10 ML durvalumab 50 MG/ML Injection"},{"code":"1991412","display":"24 ML nivolumab 10 MG/ML Injection"}]}]},"expansion":{"identifier":"urn:uuid:f8c43053-cfd5-4d40-809d-75f8bf16728d","timestamp":"2022-06-10T05:39:42-04:00","total":11,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1657005","display":"40 ML ipilimumab 5 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1657012","display":"10 ML ipilimumab 5 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1657190","display":"4 ML nivolumab 10 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1657195","display":"10 ML nivolumab 10 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1657746","display":"pembrolizumab 50 MG Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1657750","display":"4 ML pembrolizumab 25 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1792780","display":"20 ML atezolizumab 60 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1875542","display":"10 ML avelumab 20 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1919507","display":"2.4 ML durvalumab 50 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1919515","display":"10 ML durvalumab 50 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1991412","display":"24 ML nivolumab 10 MG/ML Injection"}]}}